Overview

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Status:
Active, not recruiting

Trial end date:
2023-01-17

Target enrollment:

Participant gender:

Summary

There are 2 fold of purposes for this study. 1 is to evaluate safety and tolerability and the other is to study the anti-tumor effects of talimogene laherparepvec in Japanese participants with unresectable stage IIIB-IV malignant melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Talimogene laherparepvec